Fidelity Investments
CLYM

Fidelity Investments’s Climb Bio CLYM Stock Holding History

Fidelity Investments’s Portfolio CLYM Stock Details CLYM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$88.5M Buy
6,790,364
+6,783,967
+106,049% +$70.1M ﹤0.01% 1274
2026
Q1 		$43.8K Buy
6,397
+48
+0.8% +$277 ﹤0.01% 4183
2025
Q4 		$25.4K Sell
6,349
-793
-11% -$1.9K ﹤0.01% 4376
2025
Q3 		$14.4K Sell
7,142
-485
-6% -$900 ﹤0.01% 4493
2025
Q2 		$9.46K Buy
7,627
+4,977
+188% +$6.19K ﹤0.01% 4544
2025
Q1 		$3.23K Sell
2,650
-10,913
-80% -$17.7K ﹤0.01% 4804
2024
Q4 		$24.4K Buy
13,563
+13,547
+84,669% +$49K ﹤0.01% 4135
2024
Q3 		$81 Buy
+16
New +$113 ﹤0.01% 5121
2022
Q3 		– Sell
-9
Closed – – 5490
2022
Q2 		$0 Sell
9
-85
-90% -$402 ﹤0.01% 5580
2022
Q1 		$1K Buy
+94
New +$877 ﹤0.01% 4864

Other funds holding CLYM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Fidelity Investments's CLYM Position: Q2 2026 in Review

Fidelity Investments increased its Climb Bio (CLYM) stake by 106,049% in Q2 2026, buying an estimated $70.1M and bringing the position to 6,790,364 shares worth $88.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1274.

Fidelity Investments first reported a position in CLYM in Q1 2022 and has held it in 10 quarters since. 109 funds tracked by Wall St. Rank hold CLYM as of Q2 2026.

  • Fidelity Investments held 6,790,364 shares of Climb Bio worth $88.5M as of Q2 2026.
  • Fidelity Investments bought 6,783,967 Climb Bio shares in Q2 2026, an estimated $70.1M.
  • Climb Bio made up ﹤0.01% of Fidelity Investments's portfolio in Q2 2026, its #1274 holding.
  • Fidelity Investments first reported a position in Climb Bio in Q1 2022 and has held it in 10 quarters since.
  • 109 funds tracked by Wall St. Rank held Climb Bio as of Q2 2026.

Based on Fidelity Investments's 13F filing for Q2 2026, filed 13 Aug 2026.